Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6757-6760

  Zhu, Chun Yu ^a,b   Lv, Yan Ping ^b   Yan, Deng Feng ^b   Gao, Fu Lian ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b Zhoukou Central Hospital   (China)

Author keywords

Adriamycin; Drug resistance; Gastric cancer cell; MDR1

Indexed keywords

ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84892455062     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6757     Document Type: Article

References (26)

1. Cole SP, Bhardwaj G, Gerlach JH, et al (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-4.
2. Dong X, Mumper RJ (2010). Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond), 5, 597-615.
3. Duan Z, Lamendola DE, Duan Y, et al (2005). Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol, 55, 277-85.
4. Filipits M, Malayeri R, Suchomel RW, et al (1999). Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res, 19, 5043-9.
5. Goda K, Fenyvesi F, Bacso Z, et al (2007). Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ther, 320, 81-8.
6. He Y, Bi Y, Hua Y, et al (2011). Ultrasound microbubblemediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells. J Exp Clin Cancer Res, 30, 104.
7. Hilgendorf C, Spahn-Langguth H, Rhedin M, et al (2005). Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport. Mol Pharm, 2, 64-73.
8. Hua J, Mutch DG, Herzog TJ (2005). Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol, 98, 31-8.
9. Huang C, Li Y, Cao P, Xie Z, Qin Z (2011). Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. J Huazhong Univ Sci Technolog Med Sci, 31, 488-96.
10. Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander A.R (1999). Current options in treatment of anthracyclineresistant breast cancer. Cancer Treat Rev, 25, 279-91.
11. Kruhn A., Wang A., Fruehauf JH, Lage H (2009). Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrugresistant phenotype of cancer cells. Cell Cycle, 8, 3349-54.
12. Leonard GD, Fojo T, Bates SE (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411-24.
13. Li Y, Yan PW, Huang XE, Li CG (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
14. Liu C, Zhao G, Liu J, et al (2009). Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release, 140, 277-83.
15. Liu J, Zhang Y, Xu R, et al (2013). PI3K/Akt-dependent phosphorylation of GSK3beta and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration. Cell Signal, 25, 447-56.
16. O'Driscoll L, Clynes M (2006a). Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets, 6, 365-84.
17. O'Driscoll L, Clynes M (2006b). Molecular markers of multiple drug resistance in breast cancer. Chemotherapy, 52, 125-9.
18. Ozben T (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett, 580, 2903-9.
19. Pan GD, Yang JQ, Yan LN, et al (2009). Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol, 15, 431-40.
20. Song W, Jiang R, Zhao CM (2012). Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. Asian Pac J Cancer Prev, 13, 5619-25.
21. Stege A, Kruhn A, Lage H (2010). Overcoming multidrug resistance by RNA interference. Methods Mol Biol, 596, 447-65.
22. Szakacs G, Annereau JP, Lababidi S, et al (2004). Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell, 6, 129-37.
23. Wang J, Li J, Huang Y, et al (2013). Bcl-3 suppresses Tax-induced NF-kappaB activation through p65 nuclear translocation blockage in HTLV-1-infected cells. Int J Oncol, 42, 269-76.
24. Yamauchi M, Kumazawa H, Satta T, et al (1992). Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur J Cancer, 28A, 1422-7.
25. Zhang D, Fan D (2007). Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther, 7, 1369-78.
26. Zhang KG, Qin CY, Wang HQ, Wang JX, Wang QM (2012). The effect of TRAIL on the expression of multidrug resistant genes MDR1, LRP and GST-pi in drug-resistant gastric cancer cell SGC7901/VCR. Hepatogastroenterology, 59, 2672-6.